Genialis

Boston, Massachusetts, USA · ≈32 employees · genialis.com

Genialis is a precision oncology and RNA biomarker company based in Boston, Massachusetts, founded in 2015. The company focuses on developing clinically actionable AI models to predict patient responses and guide treatment decisions for targeted therapies and immunotherapies. Genialis combines advanced AI, machine learning, and deep biological expertise to enhance patient outcomes and support drug development. The company offers a range of services, including predictive biomarker discovery, clinical trial optimization, target identification and validation, and biomarker-guided treatment decisions. Genialis collaborates with pharmaceutical and diagnostics partners to create innovative tools that improve the precision of cancer treatment. Its product lineup includes the Genialis™ Supermodel, ResponderID framework, Expressions Software, and Genialis™ krasID, all designed to provide actionable insights for oncology.

Biotechnology

Also: data fusion · machine learning · biomedical data analysis · omics data integration · precision medicine · software development · gene signature · predictive biomarker · precision oncology · healthcare · biotechnology · pharmaceuticals

Funding0

Every round, secondary, debt facility or acquisition involving Genialis that Lounge tracks, newest first.

No rounds recorded yet.

Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.

See plans →Log in

Genialis

Funding0

Key numbers

Also on Lounge